stock.adobe.photos.com - gaviAstraZeneca plc acquires SixPeaks Bio Inc to target muscle‑preserving obesity therapies, boosting its pipeline in a US$30 bn fast-growing weight-loss market.
Tag Archive for: obesity
Adobe stock photos - Dzmitry Semaglutide (Ozempic®) and Tirzepatide (Mounjaro®) not only promote weight loss but also significantly reduce the risk of major cardiovascular events in patients with type 2 diabetes. Real-world evidence from the Technical University of Munich and Harvard Medical School shows up to 18% lower risk of heart attack and stroke, highlighting the growing potential of GLP-1 therapies in cardiometabolic care.
Adobe stock photos - Matthew Eli Lilly and Novo Nordisk cut US obesity drug prices under Trump’s MFN plan, offering Zepbound, Wegovy and others via Medicare, Medicaid and LillyDirect.
Adobe stock photos - https://european-biotechnology.com/latest-news/roche-moves-obesity-asset-ct-388-into-phase-iii/Danish Novo Nordisk A/S has made an unexpected takeover bid for US biotech Metsera, Inc. This challenges the already agreed acquisition by Pfizer Inc. Novo offers US$6.5bn in cash, plus up to US$2.5bn in milestone payments. The total potential value is around US$9bn. Pfizer previously offered US$4.9bn plus US$2.4bn in milestones.
Novo NordiskNovo Nordisk is to acquire US-based Akero Therapeutics in a US$5.2 billion deal aimed at reviving growth and entering the MASH-space where others like Roche and GSK have recently expanded their footprint.
Roche AGSwiss Roche AG will advance its injectable obesity lead CT-388 into Phase III studies starting in H1/2026. With combination therapies, the Swiss pharma major aims at becoming obesity company No. 3 by 2030, Roche Pharma CEO Teresa Graham said at Roche’s Pharma Day in London.
Adobe stock photos - JimEli Lilly, the US market leader in the lucrative diabetes and obesity space, is now challenging its competitor Novo Nordisk in the area of oral GLP-1 receptor agonists. Lilly’s orforglipron has met the primary endpoint of its registration study and is set to be submitted for approval in the United States.
BioMed XNovo Nordisk has entered a collaboration with research institute BioMed X in an effort to regain market position lost to leading competitors in diabetes and obesity treatment. The partnership is focused on improving the low bioavailability of orally administered peptide-based medicines.
Max-Planck SocietyLose weight without expensive obesity pills? The discovery of a direct link between olfactory receptors and areas of the brain that signal satiety makes this seem possible, initially in mice.
asobe stock photos - catalin Roche is extending its obesity pipeline signing a US$5.3bn biobucks deal with Zealand Pharma A/S, who will co-develop and co-commercialise a monotherapy of its long-acting amylin analogue petrelintide with the Swiss pharma giant in the US and Europe and do the same for a combo of petrelintide and Roche’s GLP1/GIP receptor agonist CTT388.